ArticleInternational journal of hepatology2020
Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease.
Article in International journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.Frontiers in cellular and infection microbiology · 2022Trial
- Fecal microbiota transplant and its usefulness in hepatic disorders: a systematic review.Therapeutic advances in gastroenterology · 2026Review
- Harnessing the microbiota-gut-brain axis to prevent and treat pediatric neurodevelopmental disorders: translational insights and strategies.Journal of translational medicine · 2025Review
- Advancements in nutritional diagnosis and support strategies during the perioperative period for patients with liver cancer.World journal of gastrointestinal surgery · 2024Review
- Effect of intestinal microbiota transplantation on chronic hepatitis B virus infection associated liver disease.Frontiers in microbiology · 2024Article
- The Role of the Gastrointestinal Microbiome in Liver Disease.Pathogens (Basel, Switzerland) · 2023Review
- Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy.Antibiotics (Basel, Switzerland) · 2023Review
- Review
- The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Review
- Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.Seminars in liver disease · 2021Review
- Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Observational
- The microbiota in cirrhosis and its role in hepatic decompensation.Journal of hepatology · 2021Review
- Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.Gastroenterology · 2021Review
- Microbiota-Dependent Effects of IL-22.Cells · 2020Review
- Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFecal microbiota transplantation (FMT) is a well-established therapeutic option for patients with antibiotic resistant
aimsWe studied the effect of FMT on chronic liver disease (CLD) patients with CDI at our tertiary medical center.
methodsA cohort of all patients who received FMT from December 2012 to May 2014 for refractory or recurrent CDI was identified. Patients were monitored for a year after FMT. Descriptive analysis was conducted to compare the effect of FMT in patients with and without CLD.
resultsA total of 201 patients with CDI received FMT, 14 of which had a history of CLD. Nine of these patients exhibited cirrhosis of the liver with a mean Child-Turcotte-Pugh score of 8. CDI development in these patients was associated with recent exposure to antibiotics and was observed to be significantly different between both groups (17% of CLD patients vs. 58% in the general cohort,
conclusionFMT is a safe and effective therapy against CDI for patients with CLD and cirrhosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.